Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Jun:61 Suppl 1:S165-S174.
doi: 10.1002/jcph.1885.

Applying the Noninferiority Paradigm to Assess Exposure-Response Similarity and Dose Between Pediatric and Adult Patients

Qunshu Zhang  1 , James Travis  2 , Rebecca Rothwell  2 , Christopher E Jay  1 , Rashid Jahidur  1 , Yifei Zhang  3 , Victor Crentsil  1 , Tara Altepeter  1 , Jessica J Lee  1 , Gilbert J Burckart  3 , Charles Ganley  1 , Jian Wang  1
Affiliations
Comparative Study

Applying the Noninferiority Paradigm to Assess Exposure-Response Similarity and Dose Between Pediatric and Adult Patients

Qunshu Zhang et al. J Clin Pharmacol. 2021 Jun.

Abstract

The use of extrapolation of efficacy in pediatric drug development programs is possible when disease progression and treatment response are similar in adult and pediatric populations. Historically, the exposure-response (E-R) similarity was assessed by visual inspection of 2 E-R curves to support pediatric extrapolation. The aim of this study was to develop a quantitative framework to describe the E-R relationship and the difference in E-R between pediatric and adult patients based on accumulated experience in pediatric drug development programs. Using clinical data for 8 drugs with either a linear or nonlinear E-R relationship, we adapted the methodology used in noninferiority testing to assess the E-R similarity between adult and pediatric patients at the targeted drug exposure. We implemented bootstrap-based and Bayesian-based methodologies to estimate the probability of concluding noninferiority of the E-R relationship. This approach provides objective criteria that can be applied to an assessment of E-R noninferiority in 2 populations to support extrapolation of efficacy in drug development programs from adults to pediatric populations.

Keywords: exposure-response; extrapolation; pediatric drug development; regulatory science.

PubMed Disclaimer

References

    1. US Food and Drug Administration. Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products: Guidance for Industry. Center for Drug Evaluation and Research, 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents.... Accessed September 9, 2020.
    1. Pellock JM, Carman WJ, Thyagarajan V, et al. Efficacy of anti-epileptic drugs in adults predicts efficacy in children: a systematic review. Neurology. 2012;79(14):1482-1489.
    1. Mehrotra SM. CERSI-FDA Workshop: Quantitative Analysis to Support Full Extrapolation of Efficacy in Children for Partial Onset Seizures in Adjunctive Setting: FDA-PEACE Initiative, 2016. https://pharmacy.umaryland.edu/media/SOP/wwwpharmacyumarylandedu/centers.... Accessed December 20, 2020.
    1. US Food and Drug Administration. Gastrointestinal Drugs Advisory Committee Meeting; Remicade (infliximab), 2011. https://wayback.archive-it.org/7993/20170405221622/https://www.fda.gov/d.... Accessed May 14, 2021.
    1. US Food and Drug Administration. Darunavir Clinical Pharmacology review. Office of Clinical Pharmacology, 2012. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/Developme.... Accessed January 18, 2018.

Publication types